BACKGROUND: HIV-2 is known to be less pathogenic than HIV-1, although the underlying mechanisms are still debated. We compared the changes over time in viro-immunological markers in HIV-1 and HIV-2-infected patients living in France during natural history and after initiation of the first combination antiretroviral therapy (CART). METHOD: Patients were included in the ANRS CO3 HIV-1 cohort (N = 6707) or the ANRS CO5 HIV-2 cohort (N = 572). HIV-1-infected patients were matched to HIV-2 patients according to sex, age, HIV transmission group and period of treatment initiation. Changes in markers were estimated using linear mixed models. RESULTS: Analyses were performed for three groups of patients: those with estimated date of contamination (98 HIV-1 and 49 HIV-2-seroincident patients); untreated seroprevalent patients (320 HIV-1 and 160 HIV-2); and those initiating a first CART (59 HIV-1 and 63 HIV-2). In group 1, CD4 T-cell counts decreased less rapidly in HIV-2 than HIV-1 patients (-9 versus -49 cells/microl per year, P < 10(-4)). Results were similar in group 2. Baseline CD4 cell count at CART initiation was not different according to the type of infection. During the first 2 months of treatment, the CD4 cell count increased by +59 cells/microl per month (CI 34; 84) for HIV-1 and +24 (CI 6; 42) for HIV-2. The plasma viral load drop was threefold more important in HIV-1 patients: -1.56 log10/ml per month versus -0.62 among HIV-2 patients (P < 10(-4)). CONCLUSION: Differences between the two infections during natural history are similar to those previously described in Africa. Once treatment is started, response is poorer in HIV-2 than in HIV-1 patients.
BACKGROUND:HIV-2 is known to be less pathogenic than HIV-1, although the underlying mechanisms are still debated. We compared the changes over time in viro-immunological markers in HIV-1 and HIV-2-infectedpatients living in France during natural history and after initiation of the first combination antiretroviral therapy (CART). METHOD:Patients were included in the ANRS CO3 HIV-1 cohort (N = 6707) or the ANRS CO5 HIV-2 cohort (N = 572). HIV-1-infectedpatients were matched to HIV-2patients according to sex, age, HIV transmission group and period of treatment initiation. Changes in markers were estimated using linear mixed models. RESULTS: Analyses were performed for three groups of patients: those with estimated date of contamination (98 HIV-1 and 49 HIV-2-seroincident patients); untreated seroprevalent patients (320 HIV-1 and 160 HIV-2); and those initiating a first CART (59 HIV-1 and 63 HIV-2). In group 1, CD4 T-cell counts decreased less rapidly in HIV-2 than HIV-1patients (-9 versus -49 cells/microl per year, P < 10(-4)). Results were similar in group 2. Baseline CD4 cell count at CART initiation was not different according to the type of infection. During the first 2 months of treatment, the CD4 cell count increased by +59 cells/microl per month (CI 34; 84) for HIV-1 and +24 (CI 6; 42) for HIV-2. The plasma viral load drop was threefold more important in HIV-1patients: -1.56 log10/ml per month versus -0.62 among HIV-2patients (P < 10(-4)). CONCLUSION: Differences between the two infections during natural history are similar to those previously described in Africa. Once treatment is started, response is poorer in HIV-2 than in HIV-1patients.
Authors: B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz Journal: J Clin Microbiol Date: 2000-04 Impact factor: 5.948
Authors: Larry W Chang; Muberak Osei-Kwasi; Daniel Boakye; Simeon Aidoo; Angela Hagy; James W Curran; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2002-04-15 Impact factor: 3.731
Authors: M Ndour; P S Sow; A M Coll-Seck; S Badiane; C T Ndour; N Diakhaté; B Diop; M Faye; M Soumaré; G Diouf; R Colebunders Journal: Trop Med Int Health Date: 2000-10 Impact factor: 2.622
Authors: N A Smith; T Shaw; N Berry; C Vella; L Okorafor; D Taylor; J Ainsworth; A Choudhury; R S Daniels; S El-Gadi; A Fakoya; G Moyle; J Oxford; R Tedder; S O'Shea; A de Ruiter; J Breuer Journal: J Infect Date: 2001-02 Impact factor: 6.072
Authors: M E van der Ende; C Guillon; P H Boers; T D Ly; R A Gruters; A D Osterhaus; M Schutten Journal: J Acquir Immune Defic Syndr Date: 2000-09-01 Impact factor: 3.731
Authors: Geoffrey S Gottlieb; Papa Salif Sow; Stephen E Hawes; Ibra Ndoye; Mary Redman; Awa M Coll-Seck; Mame A Faye-Niang; Aissatou Diop; Jane M Kuypers; Cathy W Critchlow; Richard Respess; James I Mullins; Nancy B Kiviat Journal: J Infect Dis Date: 2002-03-19 Impact factor: 5.226
Authors: V Shanmugam; W M Switzer; J N Nkengasong; G García-Lerma; T A Green; E Ekpini; M Sassan-Morokro; F Antunes; K Manshino; V Soriano; S Z Wiktor; W Heneine Journal: J Acquir Immune Defic Syndr Date: 2000-07-01 Impact factor: 3.731
Authors: Boris K Tchounga; Bo L Hønge; Serge P Eholie; Patrick A Coffie; Sanne Jespersen; Christian Wejse; François Dabis; Gottlieb S Geoffrey; Didier K Ekouevi Journal: AIDS Date: 2016-11-13 Impact factor: 4.177
Authors: Rui S Soares; Rita Tendeiro; Russell B Foxall; António P Baptista; Rita Cavaleiro; Perpétua Gomes; Ricardo Camacho; Emília Valadas; Manuela Doroana; Margarida Lucas; Francisco Antunes; Rui M M Victorino; Ana E Sousa Journal: J Virol Date: 2010-12-15 Impact factor: 5.103
Authors: S M Fernandes; A R Pires; P Matoso; C Ferreira; H Nunes-Cabaço; L Correia; E Valadas; J Poças; P Pacheco; H Veiga-Fernandes; R B Foxall; A E Sousa Journal: Mucosal Immunol Date: 2017-05-17 Impact factor: 7.313
Authors: Russell B Foxall; Catarina S Cortesão; Adriana S Albuquerque; Rui S Soares; Rui M M Victorino; Ana E Sousa Journal: J Virol Date: 2008-07-23 Impact factor: 5.103
Authors: Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa Journal: PLoS Pathog Date: 2009-11-20 Impact factor: 6.823
Authors: Geoffrey S Gottlieb; Serge-Paul Eholié; John N Nkengasong; Sabelle Jallow; Sarah Rowland-Jones; Hilton C Whittle; Papa Salif Sow Journal: AIDS Date: 2008-10-18 Impact factor: 4.177